Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
China-made Ambrisentan in PAH
NCT05437224Phase 3Completed
- Sponsor
- Renji Hospital
- Start
- Dec 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by Renji Hospital. Started Dec 2018; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05437224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437224.